A phase I trial of CC-486, lenalidomide, obinutuzumab in relapsed/refractory indolent non-Hodgkin lymphoma

被引：0
|
作者：
Othman, Tamer [1 ,2 ]
Marquez-Arreguin, Gabriel [1 ]
Esteghamat, Naseem [1 ]
Tuscano, Joseph [1 ,3 ]
机构：
[1] Univ Calif Davis, Sch Med, Dept Internal Med, Div Malignant Hematol Cellular Therapy & Transplan, Sacramento, CA USA
[2] Univ Calif San Francisco, Sch Med, Dept Internal Med, Div Hematol & Oncol, San Francisco, CA USA
[3] Northern Calif Hlth Care Syst, Vet Adm, Martinez, CA USA
来源：
LEUKEMIA & LYMPHOMA | 2024年
关键词：
REFRACTORY FOLLICULAR LYMPHOMA; SINGLE-ARM; MULTICENTER; METHYLATION;
D O I：
10.1080/10428194.2024.2443552
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Phase I/II trial of clofarabine in refractory and/or relapsed non-Hodgkin's lymphoma (NHL)
    Nabhan, C.
    Fried, W.
    Galvez, A.
    Venugopal, P.
    Bitran, J. D.
    ANNALS OF ONCOLOGY, 2008, 19 : 243 - 243
  • [22] Phase I/II trial of clofarabine in refractory and/or relapsed non-hodgkin's lymphoma (NHL)
    Nabhan, C.
    Fried, W.
    Galvez, A.
    Venugopal, P.
    Gozun, P.
    Bitran, J. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [23] Phase II Trial of Lenalidomide in Patients with Relapsed or Refractory Hodgkin Lymphoma
    Kuruvilla, John
    Taylor, Diane
    Wang, Lisa
    Blattler, Chantale
    Keating, Armand
    Crump, Michael
    BLOOD, 2008, 112 (11) : 1049 - 1049
  • [24] Phase III Randomized AUGMENT Study of Lenalidomide/Rituximab vs Rituximab/Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
    Gribben, J.
    Trneny, M.
    Izutsu, K.
    Fowler, N. H.
    Hong, X.
    Zhu, J.
    Zhang, H.
    Offner, F.
    Scheliga, A.
    Nowakowski, G.
    Pinto, A.
    Re, F.
    Fogliatto, L. M.
    Scheinberg, P.
    Flinn, I.
    Moreira, C.
    Liu, D.
    Kalambakas, S.
    Fustier, P.
    Wu, C.
    Leonard, J. P.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 79 - 79
  • [25] ANALYSIS OF A PHASE 2 STUDY OF LENALIDOMIDE AND RITUXIMAB IN RELAPSED OR REFRACTORY NON-HODGKIN'S LYMPHOMA
    Dutia, M.
    DeRoock, I.
    Chee, K.
    O'Donnell, R.
    Quirch, C.
    Reed-Pease, C.
    Tuscano, J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 118 - 118
  • [26] A phase I trial of PS-341 and fludarabine for relapsed and refractory indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
    Snell, M.
    Koc, O. N.
    Bahlis, N. J.
    Liu, L.
    Lazarus, H. M.
    Gerson, S. L.
    Laughlin, M. J.
    Jacobberger, J.
    Horvath, N.
    Remick, S.
    Cooper, B. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 441S - 441S
  • [27] Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma
    Tuscano, Joseph M.
    Dutia, Mrinal
    Chee, Karen
    Brunson, Ann
    Reed-Pease, Christine
    Abedi, Mehrdad
    Welborn, Jeanna
    O'Donnell, Robert T.
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 165 (03) : 375 - 381
  • [28] A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma
    Maly, Joseph J.
    Christian, Beth A.
    Zhu, Xiaohua
    Wei, Lai
    Sexton, Jennifer L.
    Jaglowski, Samantha M.
    Devine, Steven M.
    Fehniger, Todd A.
    Wagner-Johnston, Nina D.
    Phelps, Mitch A.
    Bartlett, Nancy L.
    Blum, Kristie A.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (06): : 347 - 353
  • [29] Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma: A Phase I Trial
    Kambhampati, Swetha
    Fakhri, Bita
    Ai, Weiyun Z.
    Kaplan, Lawrence D.
    Tuscano, Joseph M.
    Wieduwilt, Matthew J.
    Sudhindra, Akshay
    Cavallone, Erika
    Reiner, Jesika
    Aoun, Charlie
    Castillo, Miguel
    Martinelli, Michelle
    Ta, Teresa
    Le, Diem
    Padilla, Michelle
    Crawford, Erika
    Andreadis, Charalambos B.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (03): : 139 - 146
  • [30] A Phase I Study of Ibrutinib and Lenalidomide in Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma
    Christian, Beth
    Kuruvilla, John
    Smith, Sonali
    Porcu, Pierluigi
    Ruppert, Amy S.
    Byrd, John C.
    Grever, Michael R.
    Blum, Kristie A.
    BLOOD, 2014, 124 (21)
12345